shadow shadow shadow shadow shadow
    Country
    Opportunity Status
    Funding Instrument Type
    Category
    Clear

    NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)

    PAR-24-116

    National Institutes of Health

    Opening date 1 Feb 2024, 12:00AM

    Closing date 13 Nov 2026, 12:00AM

    Funding Opportunity Number: PAR-24-116

    Opportunity Category: Discretionary

    CFDA Number(s): 93.213 -- Research and Training in Complementary and Integrative Health

    Cost Sharing or Matching Requirement: No

    Posted Date: Feb 01, 2024 12:00:00 AM EST

    Closing Date: Nov 13, 2026 12:00:00 AM EST

    Award Ceiling: $1050000

    Award Floor: none

    Eligible Applicants: City or township governments,Small businesses,Private institutions of higher education,County governments,Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education,Independent school districts,Native American tribal governments (Federally recognized),Native American tribal organizations (other than Federally recognized tribal governments),Public and State controlled institutions of higher education,For profit organizations other than small businesses,Public housing authorities/Indian housing authorities,Others (see text field entitled "Additional Information on Eligibility" for clarification),Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,State governments,Special district governments

    Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

    Agency Name: National Institutes of Health

    Description: This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. For this NOFO, natural products include promising nutritional regimens that standardize the amount of a specific naturally occurring nutritional compound (e.g., omega-3 fatty acids, anthocyanidins, or polyphenols) and have compelling preliminary evidence. Under this NOFO, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This NOFO will provide up to 3 years support for studies to replicate the impact of the natural product on target engagement when used by humans, and assess whether there is an association between the degree of the impact on target engagement and functional or clinical outcomes in a patient population. Applications are encouraged to design studies to determine how to optimize the impact of the natural product on target engagement by optimizing the delivery of the natural product through examination of different doses or formulations. In addition, applications can be designed to combine the natural product with another treatment approach that is known to engage the same target; or study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this NOFO are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early-stage clinical testing to determine whether continued clinical research is warranted. This NOFO will not support efficacy or effectiveness trials, nor will

    Grantor Contact Information: NIH Grants Information grantsinfo@nih.gov

    We use cookies and similar technologies that are necessary to operate the website.Please read our cookie policy.

    We use cookies and similar technologies that are necessary to operate the website. Additional cookies are only used with your consent. We use the additional cookies to perform analyses of website usage and to check marketing measures for their efficiency. These analyses are carried out to provide you with a better user experience on the website. You are free to give, deny, or withdraw your consent at any time by using the "cookie settings" link at the bottom of each page. You can consent to our use of cookies by clicking "Agree". For more information about what information is collected and how it is shared with our partners, please read our cookie policy.

    • Required to run the website
    • Monitoring website usage and optimizing the user experience
    • Evaluation of marketing actions
    • Storage of your preferences from previous visits
    • Collecting user feedback to improve our website
    • Recording of your interests in order to provide customised content and offers
    Cookie Settings Accept